×
About 2,905 results

ALLMedicine™ Retinal Vein Occlusion Center

Research & Reviews  989 results

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion
https://clinicaltrials.gov/ct2/show/NCT04740905

May 18th, 2022 - This is a Phase III, multicenter, randomized, double-masked, active comparator-controlled, parallel-group study evaluating the efficacy, safety, and pharmacokinetics of faricimab administered by intravitreal (IVT) injection at 4-week intervals unt...

Cardiovascular morbidity and all-cause mortality in patients with retinal vein occlusio...
https://doi.org/10.1136/bjophthalmol-2022-321225
The British Journal of Ophthalmology; Frederiksen KH, Stokholm L et. al.

May 11th, 2022 - Associations between retinal vein occlusion (RVO) and subsequent cardiovascular disease (CVD) or mortality have not been evaluated in a recent cohort, after novel therapeutic options have increased referrals for treatment of the condition. We aime...

Optical coherence tomography angiography as predictor of visual outcomes in retinal vei...
https://doi.org/10.1177/11206721221099487
European Journal of Ophthalmology; Mejía ME, Ríos HA et. al.

May 6th, 2022 - Evaluate optical coherence tomography angiography (OCT-A) features in retinal vein occlusions (RVO) associated with visual outcomes after anti-VEGF. Analytical observational study performed in eyes with macular edema secondary to RVO treated with ...

Changes in 12-month outcomes over time for age-related macular degeneration, diabetic m...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9066999
Eye (London, England); Bhandari S, Nguyen V et. al.

May 5th, 2022 - To identify whether the outcomes of neovascular age-related macular degeneration (nAMD), diabetic macular oedema (DMO) and retinal vein occlusion (RVO) in routine clinical practice have changed over time. We analysed 12-month outcomes in treatment...

see more →

Drugs  6 results see all →

Clinicaltrials.gov  80 results

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion
https://clinicaltrials.gov/ct2/show/NCT04740905

May 18th, 2022 - This is a Phase III, multicenter, randomized, double-masked, active comparator-controlled, parallel-group study evaluating the efficacy, safety, and pharmacokinetics of faricimab administered by intravitreal (IVT) injection at 4-week intervals unt...

Efficacy of Formulated Posterior Sub Tenon Triamcinolone in Macular Edema Secondary to Non-Ischemic Retinal Vein Occlusions
https://clinicaltrials.gov/ct2/show/NCT05345808

Apr 26th, 2022 - Retinal vein occlusion (RVO) is considered the second vascular disorder of the retina after diabetic retinopathy. Patients with RVO are at risk of the development of macular edema. Different treatment modalities for macular edema include LASER the...

Assessment of Retinal Vessel Diameters and Red Blood Velocities in Patients With BRVO and Healthy Subjects
https://clinicaltrials.gov/ct2/show/NCT01746615

Apr 7th, 2022 - Assessment of retinal vessel calibers combined with bidirectional Fourier domain optical coherence tomography (FDOCT) for measurement of retinal blood velocities is a new and sophisticated method for assessing retinal blood flow in humans. The val...

Spectral-domain Optical Coherence Tomography Findings in Retinal Vessel Occlusion
https://clinicaltrials.gov/ct2/show/NCT03061526

Mar 23rd, 2022 - Several studies tried to classify retinal ischemia due to retinal artery or vein occlusion into different grades. In some cases prognosis is dependent on grade of severity, especially in cases of retinal vein occlusion. State of the art to Diagnos...

Functional and Anatomical Outcomes of Dexamethasone Intra-vitreal Implant in Patients With Macular Edema Due to Retinal Vein Occlusion
https://clinicaltrials.gov/ct2/show/NCT05003258

Mar 14th, 2022 - Aim of the research is To evaluate functional and anatomical outcomes of ozurdex injection in patients with RVO related macular edema. And evaluation of the safety of ozurdex injections regarding intraocular pressure increase, cataract development...

see more →

News  85 results

COVID-19 May Increase Risk for Rare Eye Clots
https://www.medscape.com/viewarticle/972265

Apr 18th, 2022 - (Reuters) - Patients with COVID-19 may have an increased risk of rare vision-threatening blood clots in the eye for months afterward, new findings suggest. Because SARS-CoV-2 infections increase the risk of blood vessel obstructions at other sites...

Vision-Threatening Retinal Condition Linked to COVID-19
https://www.medpagetoday.com/ophthalmology/generalophthalmology/98212

Apr 14th, 2022 - COVID-19 infection may be boosting the numbers of a rare ocular condition in which vision is threatened when veins in the retina are blocked, eye specialists in Southern California report. Risk of retinal vein occlusion was higher in the 6 months ...

FDA Approves First Biosimilar for Ranibizumab Intravitreal Injections, nAMD
https://www.medscape.com/viewarticle/959087

Sep 20th, 2021 - The US Food and Drug Administration (FDA) has approved the first biosimilar for ophthalmology, Byooviz (ranibizumab-nuna), which will be indicated for neovascular (wet) age-related macular degeneration (nAMD), macular edema following retinal vein ...

COVID Delay of Treatment of Neovascular Age-Related Macular Degeneration Less Harmful Than Expected
https://www.medscape.com/viewarticle/950709

May 6th, 2021 - Many people with neovascular age-related macular degeneration (nAMD) lost less vision than expected during treatment delays imposed by COVID-19, researchers say. The finding suggests that physicians may be overtreating these patients, said James T...

Novel Agents Revolutionize Melanoma Treatment
https://www.onclive.com/view/novel-agents-revolutionize-melanoma-treatment

Dec 5th, 2020 - The mechanism of action of vemurafenib (Zelboraf) in inhibiting BRAF activity. Until recently, the cornerstone of therapy for metastatic melanoma had been chemotherapy with dacarbazine (DTIC) and immunotherapy with high-dose interleukin-2 (HD IL-...

see more →

Patient Education  2 results see all →